Albany, NY -- (SBWIRE) -- 12/10/2018 -- DelveInsight has announced the addition of the "Multiple Myeloma - Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Multiple Myeloma for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, the UK) and Japan. The Report also covers the overview, treatment practices and Multiple Myeloma forecasted epidemiology from 2018 to 2027, segmented by seven major markets.

Multiple Myeloma is a neoplasm of clonal plasma cells which originate from the post-germinal lymphoid B-cell lineage and develop after lineage commitment in the bone marrow of progenitor cell. It is associated with substantial morbidity and mortality, characterized by end organ damage - renal impairment, hypercalcemia, lytic bony lesions, and anaemia. It does not occur as the form of a lump or a tumour. It includes the division of cells and expansion of cells within the bone marrow. Thus, it leads to the destruction of the bones and affecting the production of healthy blood cells. Multiple Myeloma incident cases are increasing with an increase in the ageing population. It is more common among the males as compared to females.

In the United States, the lifetime risk of getting multiple myeloma is 1 in 143. About 30,770 new multiple myeloma cases will be diagnosed (16,400 in men and 14,370 in women) in 2018 in the United States. Myeloma is the 19th most common cancer in the UK, accounting for 2% of all new cancer cases (approximately 5,540 new cases were diagnosed in 2015). Multiple myelomas are a less frequent cancer site among both sexes. On a worldwide scale, it is estimated that about 86,000 incident cases occur annually (47,000 males and 39,000 females), accounting for about 0.8% of all new cancer cases. About 63,000 subjects are reported to die from the disease each year (33,000 males and 30,000 females), accounting for 0.9% of all cancer deaths.

Myeloma incidence is strongly related to age, with the highest incidence rates being in older people. In the UK in 2013-2015, on average each year almost half (45%) of new cases were in people aged 75 and over. An estimated 17,600 people who had been diagnosed with myeloma between 1991 and 2010 were alive in the UK at the end of 2010.

Geography Covered
1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies
1. Janssen Research & Development
2. AbbVie Inc.
3. Bristol Myers Squibb
4. Millennium Pharmaceuticals Inc.
5. Karyopharm Therapeutics
And many others

Drugs covered

1. Ponesimod
2. Empliciti in combination with lenalidomide and dexamethasone
3. Ixazomib
4. Selinexor
And many others

Report Scope
The report covers a descriptive overview of the Multiple Myeloma, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Multiple Myeloma disease and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Multiple Myeloma are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Multiple Myeloma market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Multiple Myeloma market